Stocks · News reference

Ultragenyx to Host Third Quarter 2026 Financial Results Conference Call

Oct 27, 2026, 9:31 PM

Ultragenyx Pharmaceutical Inc. announced it will hold a conference call on November 3, 2026, to discuss its financial results and provide a corporate update for the third quarter ending September 30, 2026.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RARE

Source: fiscal.ai
Observed: Oct 27, 2026, 9:31 PM
Checked: Oct 27, 2026, 9:32 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 19, 2026, 1:11 PMBenzinga Newsdesk
Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending
RARE
SEC EDGAROct 19, 2026, 1:00 PMSEC EDGAR
8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)
Filed: 2026-10-19 AccNo: 0001193125-26-424739 Size: 147 KB Item 8.01: Other Events
RARE
BenzingaOct 15, 2026, 9:31 PMBenzinga Newsdesk
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16
RARE

Ultragenyx to Host Third Quarter 2026 Financial Results Conference Call

Connected Markets

Related Headlines

Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending

8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)

UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16